Sexual Infantilism: Clinical Trials

6 trials for Sexual Infantilism, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 6 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 36Completed 3, Active not recruiting 1, Not yet recruiting 1, Recruiting 1

Follow Sexual Infantilism: new trials by email Literature Review of Sexual Infantilism trials Research Report on Sexual Infantilism

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
SEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years
Semaglutide (Wegovy) weekly injection, Placebo weekly Injection - Craniopharyngioma, Child
Phase 3Not yet recruitingUniversity Hospital, Angers502026-12-012026-11-19
A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)
Setmelanotide, Placebo - Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form
Phase 3RecruitingRhythm Pharmaceuticals, Inc.392025-09-232026-02-12
Open-Label Extension Study of Setmelanotide
Setmelanotide - Obesity Associated With Defects in Leptin-melanocortin Pathway
Phase 3CompletedRhythm Pharmaceuticals, Inc.282024-10-212026-07-15
A Trial of Setmelanotide in Acquired Hypothalamic Obesity
Setmelanotide, Placebo - Hypothalamic Obesity
Phase 3Active not recruitingRhythm Pharmaceuticals, Inc.1432023-04-262026-08-10
Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy
Exenatide, Placebo - Craniopharyngiomas, Hypothalamic Obesity
Phase 3CompletedUniversity Hospital, Bordeaux422017-01-112026-05-22
Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity
Exenatide, placebo - Hypothalamic Obesity
Phase 3CompletedSeattle Children's Hospital422016-03-012022-05-05

Narrower conditions

Craniopharyngioma (2)  ·  Obesity (2)  ·  Optic Nerve Hypoplasia (1)  ·  Septo-Optic Dysplasia (1)  ·  Weight Loss (1)

Broader conditions

Congenital Abnormalities (6)  ·  Congenital, Hereditary, and Neonatal Diseases and Abnormalities (6)  ·  Disorders of Sex Development (6)  ·  Endocrine System Diseases (6)  ·  Female Urogenital Diseases (6)  ·  Female Urogenital Diseases and Pregnancy Complications (6)  ·  Gonadal Disorders (6)  ·  Gonadal Dysgenesis (6)  ·  Hypogonadism (6)  ·  Male Urogenital Diseases (6)  ·  Urogenital Abnormalities (6)  ·  Urogenital Diseases (6)  ·  Body Weight (2)  ·  Neoplasms (2)  ·  Neoplasms by Histologic Type (2)

Interventions

setmelanotide (3)  ·  Exenatide (2)  ·  semaglutide (1)

Sponsors

Rhythm Pharmaceuticals, Inc. (3)  ·  Seattle Children's Hospital (1)  ·  University Hospital, Angers (1)  ·  University Hospital, Bordeaux (1)

Countries

United States (4)  ·  France (2)  ·  United Kingdom (2)  ·  Canada (1)  ·  Germany (1)  ·  Japan (1)  ·  Netherlands (1)

Top investigators

David Meeker, MD (3)  ·  Blandine Gatta-Cherifi, Pr (1)  ·  Christian Roth, MD (1)  ·  Paul Perez, Dr (1)

Results publications

PMID 38450721, PMID 42418774, PMID 42528856, PMID 42821228